Overview

Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Hutchison Pharmaceuticals Limited
Collaborator:
Beijing Tiantan Hospital